Related Experiment Video
Updated: May 17, 2025
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Mobilizing a New Era in Lennox-Gastaut Syndrome Treatment and Prevention
Aaron E L Warren1, Anup D Patel2,3, J Helen Cross4
1Department of Neurosurgery, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Insights
Lennox-Gastaut syndrome (LGS) is a severe childhood epilepsy. Recent breakthroughs offer hope for new treatments and prevention strategies for this challenging condition.
Area of Science:
- Pediatric Neurology
- Epileptology
- Developmental Neuroscience
Background:
- Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy in childhood.
- LGS presents with diverse etiologies but shares core electroclinical features: multiple seizure types, specific EEG patterns (slow spike-wave, generalized paroxysmal fast activity), and intellectual disability.
- The condition is typically refractory to existing therapies, imposing significant burdens on healthcare and quality of life.
Purpose of the Study:
- To summarize key advancements in Lennox-Gastaut syndrome (LGS) presented at the Pediatric State of the Art Symposium.
- To highlight recent breakthroughs in research, clinical care, and outcome measurement for LGS.
- To foster a more hopeful outlook for treatment and prevention of LGS.
Main Methods:
- Review of content presented at the American Epilepsy Society's annual meeting in December 2024.
- Focus on symposia dedicated to Lennox-Gastaut syndrome (LGS).
- Synthesis of information regarding research, clinical practice, and outcome assessment in LGS.
Main Results:
- Recent breakthroughs in LGS research have been identified.
- Advances in clinical care and outcome measurement for LGS were discussed.
- The symposium underscored progress across clinical, scientific, and patient advocacy domains.
Conclusions:
- The collective efforts of the clinical, scientific, and patient advocacy communities are paving the way for a new era in LGS management.
- There is emerging optimism for improved treatment and prevention strategies for Lennox-Gastaut syndrome.
- Continued collaboration is crucial to translate recent advancements into tangible benefits for individuals with LGS.
Abstract:
This review summarizes content presented at the Pediatric State of the Art Symposium held during the American Epilepsy Society's annual meeting in December 2024. The symposium focused on Lennox-Gastaut syndrome (LGS), a severe developmental and epileptic encephalopathy that emerges in childhood. Despite its diverse etiologies, LGS is defined by a convergent constellation of electroclinical features: multiple seizure types including tonic seizures, slow spike-wave and generalized paroxysmal fast activity on EEG, and intellectual disability. LGS is almost always refractory to available therapies and accounts for substantial costs-in healthcare spending and in quality of life for affected individuals, their families, and caregivers. The symposium highlighted recent breakthroughs in research, clinical care, and outcome measurement that have positioned the clinical, scientific, and patient advocacy communities to usher in a new, more hopeful era of treatment and prevention.
Related Concept Videos
01:28Drug Therapy
Antianxiety Medications
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:24Mania and Antimanic Drugs: Overview
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...